pharmaphorum October 18, 2024
Sanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclear fuel company Orano.
The transaction builds on a three-way partnership between Sanofi, Orano Med, and RadioMedix – signed in September with a €100 million upfront payment – to develop a radioligand therapy (RLT) for rare neuroendocrine tumours (NETs) called AlphaMedix (212Pb-dotamtate).
The programme has completed phase 2 trials and discussions are underway with regulators over possible filings. If approved, the RLT could become a competitor to Novartis’ Lutathera (177Lu-oxodotreotide). It has been awarded breakthrough status from the US FDA as a treatment for gastroenteropancreatic NETs.
Sanofi’s investment raises...
Today's Sponsors
Today's Sponsor